Non‐serious adverse events: leukopenia · primary hepatocellular carcinoma
It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: leukopenia compared with TACE (very low certainty).
1 finding from 1 review
Adverse effects after treatment initiation: injection site reactions, neutropenia, infections, demyelinating disease, heart failure, malignancy, and induction of autoimmunity. · children diagnosed with Kawasaki disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grade 3 to 4 neutropenia · adjuvant therapy for early breast cancer
Taxane followed by anthracyclines leads to lower adverse events: neutropenia (grade 3/4) ( compared with anthracyclines followed by taxane (high certainty).
1 finding from 1 review
Grade 3 to 4 neutropenia · neoadjuvant therapy for early breast cancer
Taxane followed by anthracyclines showed no clear difference in adverse events: neutropenia (grade 3/4) ( compared with anthracyclines followed by taxane (moderate certainty).
1 finding from 1 review
Intervention not reported
Meropenem plus daptomycin (No direct RCT) · people with cirrhosis and spontaneous bacterial peritonitis
It is very uncertain whether the intervention changes meropenem plus daptomycin (No direct RCT) (very low certainty).
1 finding from 1 review
HR 0.64 [0.05, 6.13]
Studies not reported
Very low
Leucopenia · Patients with maintenance treatment in lupus nephritis
Azathioprine (AZA) may leads to higher leucopenia compared with mycophenolate mofetil (MMF) (low certainty).
1 finding from 1 review
HCP used 'open questions' · Healthcare professionals working with people who have cancer
1 finding from 1 review
Thrombocytopenia (up to 3 months)n · people with cancer with thrombosis prophylaxis and central venous catheters
Low‐molecular‐weight heparin (LMWH) probably leads to higher thrombocytopenia (up to 3 months)n compared with vitamin K antagonist (VKA) (moderate certainty).
1 finding from 1 review
Thrombocytopenia · people with cancer with thrombosis prophylaxis and central venous catheters
Low‐molecular‐weight heparin (LMWH) showed no clear difference in thrombocytopenia (up to 3 months) compared with no LMWH (low certainty).
1 finding from 1 review
Thrombocytopenia · patients with active cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thrombocytopenia (main analysis‐ active cancer) · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis showed no clear difference in thrombocytopenia (main analysis‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Neutropenia · People with advanced non‐small cell lung cancer
Gefitinib leads to lower neutropenia compared with chemotherapy (high certainty).
1 finding from 1 review
Febrile neutropenia · People with advanced non‐small cell lung cancer
Gefitinib leads to lower febrile neutropenia compared with chemotherapy (high certainty).
1 finding from 1 review
Subgroup analysis:Incidence of parastomal hernia (open surgery) ( · individuals having a stoma formation
Prosthetic mesh placement probably leads to lower subgroup analysis:Incidence of parastomal hernia (open surgery) ( compared with standard treatment (moderate certainty).
1 finding from 1 review
Thrombocytopenia · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in thrombocytopenia compared with UFH prophylaxis (moderate certainty).
1 finding from 1 review
Thrombocytopenia · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in thrombocytopenia compared with fondaparinux prophylaxis (low certainty).
1 finding from 1 review
The incidence and severity of toxicities: leukopenia (WHO grade 3 to 4) · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion showed no clear difference in the incidence and severity of toxicities: leukopenia (WHO grade 3 to… compared with no treatment (low certainty).
1 finding from 1 review
The incidence and severity of toxicities: leukopenia (WHO grade 3 to 4) · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion + conventional treatment showed no clear difference in the incidence and severity of toxicities: leukopenia (WHO grade 3 to… compared with conventional medicine alone (low certainty).
1 finding from 1 review
Thrombocytopenia · people with connective tissue disease‐associated interstitial lung disease
Cyclophosphamide showed no clear difference in adverse events: thrombocytopenia 12‐month compared with mycophenolate (low certainty).
1 finding from 1 review
Adverse effects: leukopenia · people with connective tissue disease‐associated interstitial lung disease
Cyclophosphamide may leads to higher adverse events: leukopenia 12‐month compared with mycophenolate (low certainty).
1 finding from 1 review